Organization
Chugai Pharmaceutical
8 clinical trials
5 abstracts
Clinical trial
A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMAStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)Status: Not yet recruiting, Estimated PCD: 2026-06-30
Clinical trial
A Phase I Open-label, Multicenter Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2028-12-31
Clinical trial
A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2025-03-31
Clinical trial
A Phase Ia/Ib Open-label, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of ROSE12 as a Single Agent and in Combination With Other Anti-tumor Agents in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-31
Clinical trial
A Double-Blind, Placebo-Controlled, Randomized Clinical Pharmacology Study to Evaluate the Prevention Effect and the Recovery-Promoting Effect of a Single Subcutaneous Administration of GYM329 on Disuse Muscle Atrophy in Healthy Male VolunteersStatus: Completed, Estimated PCD: 2022-06-03
Clinical trial
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety, Tolerability, Pharmacokinetics, and Biomarkers of DONQ52 in Celiac Disease Patients (LILY Study)Status: Recruiting, Estimated PCD: 2024-05-31
Abstract
OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario 12 de Octubre, Charite-Universitaetsmedizin, Berlin, Germany, Chugai Pharmaceutical, Anaveon,
Abstract
Long-term effectiveness and treatment sequences in patients with extensive stage small cell lung cancer receiving atezolizumab plus chemotherapy: Results of the IFCT-1905 CLINATEZO real-world study.Org: Hôpitaux Nord-Ouest, Univ Rouen Normandie, LITIS Lab QuantIF team EA4108, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU).Org: Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France, Institut Curie, Saint Cloud, France, Univ Rouen Normandie, CHU Rouen, Inserm CIC-CRB 1404,
Abstract
ANTI-ALPHA-ACTININ ANTIBODIES COMPLEMENT ANTI-DS-DNA IN SYSTEMIC LUPUS ERYTHEMATOSUSOrg: Immunology, UKM, Muenster, Germany, Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Internal Medicine, Thomas Jefferson University, Philadelphia, United States, Chugai Pharmaceutical, Brest,
Abstract
ADULT ONSET STILL'S DISEASE: SENSITIVITY OF THE YAMAGUCHI AND FAUTREL CRITERIAOrg: Rheumatology, Society of Patients with Rheumatism, Cracow, Poland, Infectiology, Chugai Pharmaceutical, Angers, France,